Exercise trial finds attention gains after breast cancer, but primary cognitive outcomes remain negative

A remotely delivered exercise program improved attention measures in breast cancer survivors but did not significantly outperform wellness coaching on processing speed or self-reported cognition, according to research published September 30 in the Journal of the National Cancer Institute. The mixed findings help define what exercise support may offer people experiencing cognitive difficulties after treatment.

A companion paper from the same trial reported slower changes in two blood-based epigenetic aging measures. Together, the reports connect survivorship care with healthy-aging research, while leaving open whether the biomarker changes predict lasting improvements in everyday function.

What the trial tested

The randomized I Can! trial enrolled 253 breast cancer survivors. Participants were women aged 40 or older, within five years of a stage I–III diagnosis and at least six months beyond active treatment. They reported low physical activity and cognitive difficulties.

Researchers compared exercise coaching delivered largely remotely with a health-and-wellness program offering coaching contacts at the same frequency. The study included a six-month intervention followed by six months of maintenance. Assessments covered processing speed, perceived cognitive ability, attention, memory and executive function.

The contact-matched comparison strengthens the design: it helps distinguish the exercise program’s effects from the possible benefits of receiving regular support. It also means the findings describe the added value of exercise coaching over another supportive program, rather than over receiving no help.

Benefits were selective

Both groups improved across cognitive measures. The exercise group showed greater attention improvement at six and 12 months. A memory advantage appeared at six months but was no longer evident at 12 months, and executive function did not differ significantly between groups.

The absence of a significant advantage on processing speed and self-reported cognition—the two primary outcomes—limits a broad claim that the intervention improved cognition overall. Attention and memory findings deserve further investigation, but secondary outcomes do not replace the main tests the study was designed to assess.

In its September 30 research announcement, UC San Diego emphasized the relevance of attention to following conversations, absorbing information and completing tasks. Translating better test performance into durable improvements in those activities remains an important question for subsequent studies.

Aging markers add a separate signal

The companion analysis examined 124 participants with blood samples available at baseline, six months and 12 months. Researchers assessed DNA methylation, chemical markings used by epigenetic clocks to estimate aspects of biological aging.

The exercise group showed slower epigenetic aging on GrimAge2 and DNAmFitAge. Several other clock measures did not show significant changes in age acceleration. That inconsistency matters: different clocks capture different biological patterns, so the result cannot be generalized to every measure of aging.

This was a secondary analysis of a subset of the trial. The authors acknowledged its modest size, possible differences between included and excluded participants, and limited generalizability from a predominantly White, well-educated population. Changes in blood markers also cannot establish that exercise prevented dementia, extended life or reduced cancer recurrence.

What the evidence supports

The practical contribution is a more specific research direction for cognitive health after cancer: test whether remotely supported activity can produce reproducible attention benefits and meaningful improvements in daily life.

Larger and longer studies will need to establish whether those benefits persist and whether epigenetic changes help explain them. For now, the clinical findings and the aging-marker results offer complementary evidence, with distinct limits on what each can demonstrate.